Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 3,154 matching trials from the live ClinicalTrials.gov search.

Filters: San Antonio, Texas Clear all

Conditions: Geographic Atrophy
Interventions: SAR446597, Sham Comparator; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 60 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 31
States / cities: Peoria, Arizona • Scottsdale, Arizona • Beverly Hills, California + 25 more

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions: Tirzepatide, Retatrutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 4,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 141
States / cities: Tuscaloosa, Alabama • Chandler, Arizona • Gilbert, Arizona + 122 more

Conditions: Solid Malignancies, Hematologic Malignancies
Interventions: IM-1021; Drug
Lead sponsor: Immunome, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 19
States / cities: Duarte, California • Los Angeles, California • Denver, Colorado + 16 more

Conditions: Post Traumatic Stress Disorder
Interventions: Transcranial Direct Current Stimulator, Written Exposure Therapy; Device · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Urethral Stricture
Interventions: Optilume Drug Coated Balloon (DCB), Control Treatment; Device
Lead sponsor: Urotronic Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 21
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Daytona Beach, Florida + 17 more

Conditions: Non-alcoholic Steatohepatitis
Interventions: Placebo, PF-06835919; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 86
States / cities: Gilbert, Arizona • Tempe, Arizona • Anaheim, California + 50 more

Conditions: Schizophrenia
Interventions: Test strategy for implementation guideline; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • New Orleans, Louisiana • Tuscaloosa, Maryland + 3 more

Conditions: Dental Caries
Interventions: Spectra Device, DIAGNOdent; Device
Lead sponsor: The National Dental Practice-Based Research Network; Network
Eligibility: 6 Years and older
Enrollment: 3,085 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 6
States / cities: Birmingham, Alabama • Gainesville, Florida • Minneapolis, Minnesota + 3 more

Conditions: Covid19
Interventions: Observational; Other
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 14
States / cities: Los Angeles, California • Aurora, Colorado • Orlando, Florida + 7 more

Conditions: Neovascular Age-Related Macular Degeneration (nAMD)
Interventions: KHK4951, Aflibercept Injection; Drug
Lead sponsor: Kyowa Kirin Co., Ltd.; Industry
Eligibility: 50 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 38
States / cities: Mesa, Arizona • Tucson, Arizona • Arcadia, California + 34 more

Conditions: Breast Cancer
Interventions: GDC-0587, Giredestrant, Omeprazole; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Grand Rapids, Michigan • San Antonio, Texas

Conditions: Covid19, Post-acute COVID-19 Respiratory Disease
Interventions: LYT-100, Placebo; Drug · Other
Lead sponsor: PureTech; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Birmingham, Alabama • Florence, Alabama • Los Angeles, California + 12 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine, Zidovudine; Drug
Lead sponsor: Dupont Merck; Industry
Eligibility: 13 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 30 more

Conditions: Ovarian Cancer
Interventions: Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 50 Years to 74 Years · Female only
Enrollment: 8,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2028
U.S. locations: 12
States / cities: Miami, Florida • Des Moines, Iowa • Minneapolis, Minnesota + 8 more

Conditions: Placental Dysfunction, Prenatal Stress
Interventions: MOMS Intervention; Behavioral
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Brain and Central Nervous System Tumors
Interventions: irinotecan hydrochloride, temozolomide; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 9
States / cities: Los Angeles, California • San Francisco, California • Bethesda, Maryland + 6 more

Conditions: AIDS, HIV Infections
Interventions: No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP, Standard ART vs Mega ART; Other · Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 29
States / cities: Phoenix, Arizona • Long Beach, California • Palo Alto, California + 26 more

Conditions: Proliferative Diabetic Retinopathy (PDR)
Interventions: Aflibercept 8mg; Drug
Lead sponsor: Edward Wood, MD; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Austin, Texas • Bellaire, Texas • San Antonio, Texas

Conditions: Solid Tumor, Adult
Interventions: EOS100850, Pembrolizumab, Chemotherapy; Drug
Lead sponsor: iTeos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Michigan Center, Michigan • Hackensack, New Jersey • San Antonio, Texas

Conditions: Melanoma (Skin)
Interventions: aldesleukin, filgrastim, recombinant interferon alfa, cisplatin, dacarbazine, vinblastine; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 94
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more

Conditions: Osteoarthritis of the Knee
Interventions: honeybee venom (Apitoxin (Korea) Apitox (USA)); Drug
Lead sponsor: Apimeds, Inc.; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Pinellas Park, Florida • Chicago, Illinois • Columbus, Ohio + 1 more

Conditions: Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis
Interventions: Open-Label Envudeucitinib, Blinded Envudeucitinib, Placebo; Drug
Lead sponsor: Alumis Inc; Industry
Eligibility: 18 Years and older
Enrollment: 1,680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 92
States / cities: Birmingham, Alabama • Chandler, Arizona • Pheonix, Arizona + 79 more

Conditions: Cardiovascular Disorder, Classic Hodgkin Lymphoma, Clonal Hematopoiesis
Interventions: Archive Sample Retrieval, Biospecimen Collection, Electronic Health Record Review, Magnetic Resonance Imaging, Survey Administration; Procedure · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 7 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 35
States / cities: Mobile, Alabama • Phoenix, Arizona • Duarte, California + 31 more

Conditions: Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions: UGN-102, TURBT; Drug · Procedure
Lead sponsor: UroGen Pharma Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 33
States / cities: Tucson, Arizona • Loma Linda, California • Los Angeles, California + 30 more

Search by objective public record fields.

A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

Noninvasive Brain Stimulation Combined With Written Exposure Therapy for PTSD in Military Personnel With TBI

ROBUST III- Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease

A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

A Multi-Site Study of Strategies for Implementing Schizophrenia Guidelines

Decision Aids for the Management of Suspicious Occlusal Caries Lesions

Blood Purification With Seraph 100 Microbind Affinity Blood Filter for Treatment of Severe COVID19 Observational Study

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

LYT-100 in Post-acute COVID-19 Respiratory Disease

A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients

Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women

Effects of Pregnancy-Specific Anxiety on Placental Inflammatory and Oxidative Stress Response and Birth Outcomes

Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma

CSP #512 - Options in Management With Anti-Retrovirals

High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes

First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer

Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma

Apitox, Honeybee Venom Treatment for Osteoarthritis Pain and Inflammation

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma

A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer